Pleural Effusion is an indication for drug development with over 10 pipeline drugs currently active. According to GlobalData, preregistered drugs for Pleural Effusion have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Pleural Effusion compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pleural Effusion overview
Pleural Effusion also known as fluid in lungs is a condition where accumulation of fluid in pleural space of lungs observed. Underlying disease conditions of the lungs like pneumonia, emphysema, TB, etc, and other conditions like CKD, heart failure, and pancreatitis can also cause pleural effusion, and sometimes the etiology is unknown. It is usually classified as transudates and exudates. Normal pleural fluid count in healthy individuals is 0.1 ml/kg to 0.3 ml/kg and is constantly exchanged any disturbance in this exchange can result in this condition. Symptoms can be predictable or asymptomatic but, in most cases, we observe breathlessness, difficulty during cough, sometimes presented with fever, and other systematic symptoms. Chest radiography is performed to diagnose this condition and others like fluid pH, fluid protein, albumin and LDH, fluid glucose, fluid triglyceride, fluid cell count differential, fluid gram stain and culture, and fluid cytology. Treatment is based on targeting the cause. If it is caused by underlying tuberculosis antibiotic therapy is preferred. In complicated cases, fluid drainage is done and, in some cases, surgery is chosen.
For a complete picture of PTSR and LoA scores for drugs in Pleural Effusion, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
